Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination

Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitop...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 13; no. 2; p. 140
Main Authors Nishiyama, Ayae, Nogimori, Takuto, Masuta, Yuji, Matsuura, Tomoka, Kase, Tetsuo, Kondo, Kyoko, Ohfuji, Satoko, Nakagama, Yu, Kaku, Natsuko, Nakagama, Sachie, Nitahara, Yuko, Takahashi, Yoshimasa, Kakeya, Hiroshi, Kido, Yasutoshi, Fukushima, Wakaba, Yamamoto, Takuya
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 28.01.2025
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12–14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusion: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
AbstractList Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12-14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12–14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusions: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12–14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusions: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12-14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusions: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12-14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusions: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA stem domain, particularly the long α-helix (LAH) epitope, is a focus of universal vaccine research due to its cross-protective potential. Additionally, Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are recognized as important protective immune mechanisms. This study evaluated IgG responses to the HA head, stem, and LAH regions and assessed cross-reactive potential through neutralization, ADCC, and ADCP assays. Methods: IgG responses to the HA head, stem, and LAH regions were measured in vaccinated individuals. Functional assays were conducted for neutralization, ADCC, and ADCP to evaluate the association between antibody levels and immune function. Results: The results showed that HA head-specific IgG increased significantly after vaccination in 50 individuals, whereas stem-specific IgG increased by 72% and LAH-specific IgG by 12–14%. Among the induced antibody subclasses, IgG1 was predominantly increased. Neutralization titers were detected in viruses of the same strain as the vaccine strain, but not in classical or pandemic strains (H5N1, H7N9). HA stem-specific IgG1 antibody titers showed a significant correlation with ADCC/ADCP activity breadth, but no correlation was observed with neutralization breadth. Conclusion: These findings suggest that although current influenza vaccines can induce HA stem-targeted cross-reactive antibodies, their quantity may be insufficient for broad cross-protection, underscoring the need for improved vaccine strategies.
Audience Academic
Author Kakeya, Hiroshi
Nitahara, Yuko
Yamamoto, Takuya
Kido, Yasutoshi
Kase, Tetsuo
Nakagama, Yu
Masuta, Yuji
Matsuura, Tomoka
Takahashi, Yoshimasa
Fukushima, Wakaba
Kondo, Kyoko
Kaku, Natsuko
Ohfuji, Satoko
Nishiyama, Ayae
Nogimori, Takuto
Nakagama, Sachie
AuthorAffiliation 5 Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
1 Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan; anishiyama@nibiohn.go.jp (A.N.); tnogimori@nibiohn.go.jp (T.N.); y-masuta@nibiohn.go.jp (Y.M.)
6 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; ytakahas@niid.go.jp
9 Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan
8 Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka 545-0051, Japan
2 Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan; h21594d@omu.ac.jp (T.M.); kasetetsuo@omu.ac.jp (T.K.); satoko@omu.ac.jp (S.O.); wakaba@omu.ac.jp (W.F.)
3 R
AuthorAffiliation_xml – name: 2 Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan; h21594d@omu.ac.jp (T.M.); kasetetsuo@omu.ac.jp (T.K.); satoko@omu.ac.jp (S.O.); wakaba@omu.ac.jp (W.F.)
– name: 5 Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
– name: 6 Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; ytakahas@niid.go.jp
– name: 7 Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
– name: 10 Department of Virology and Immunology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
– name: 8 Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka 545-0051, Japan
– name: 1 Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka 567-0085, Japan; anishiyama@nibiohn.go.jp (A.N.); tnogimori@nibiohn.go.jp (T.N.); y-masuta@nibiohn.go.jp (Y.M.)
– name: 9 Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan
– name: 3 Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan; nakagama.yu@omu.ac.jp (Y.N.); kaku@omu.ac.jp (N.K.); d21385x@omu.ac.jp (S.N.); e21499e@omu.ac.jp (Y.N.); kakeya@omu.ac.jp (H.K.); kidoyasu@omu.ac.jp (Y.K.)
– name: 4 Management Bureau, Osaka Metropolitan University Hospital, Osaka 545-8585, Japan; kyou@omu.ac.jp
Author_xml – sequence: 1
  givenname: Ayae
  surname: Nishiyama
  fullname: Nishiyama, Ayae
– sequence: 2
  givenname: Takuto
  orcidid: 0000-0002-6011-9631
  surname: Nogimori
  fullname: Nogimori, Takuto
– sequence: 3
  givenname: Yuji
  orcidid: 0000-0003-2349-6320
  surname: Masuta
  fullname: Masuta, Yuji
– sequence: 4
  givenname: Tomoka
  surname: Matsuura
  fullname: Matsuura, Tomoka
– sequence: 5
  givenname: Tetsuo
  surname: Kase
  fullname: Kase, Tetsuo
– sequence: 6
  givenname: Kyoko
  orcidid: 0000-0003-1567-0667
  surname: Kondo
  fullname: Kondo, Kyoko
– sequence: 7
  givenname: Satoko
  orcidid: 0000-0003-3239-5249
  surname: Ohfuji
  fullname: Ohfuji, Satoko
– sequence: 8
  givenname: Yu
  surname: Nakagama
  fullname: Nakagama, Yu
– sequence: 9
  givenname: Natsuko
  surname: Kaku
  fullname: Kaku, Natsuko
– sequence: 10
  givenname: Sachie
  surname: Nakagama
  fullname: Nakagama, Sachie
– sequence: 11
  givenname: Yuko
  surname: Nitahara
  fullname: Nitahara, Yuko
– sequence: 12
  givenname: Yoshimasa
  surname: Takahashi
  fullname: Takahashi, Yoshimasa
– sequence: 13
  givenname: Hiroshi
  orcidid: 0000-0002-6251-1696
  surname: Kakeya
  fullname: Kakeya, Hiroshi
– sequence: 14
  givenname: Yasutoshi
  orcidid: 0000-0003-3615-2631
  surname: Kido
  fullname: Kido, Yasutoshi
– sequence: 15
  givenname: Wakaba
  surname: Fukushima
  fullname: Fukushima, Wakaba
– sequence: 16
  givenname: Takuya
  orcidid: 0000-0003-3753-1211
  surname: Yamamoto
  fullname: Yamamoto, Takuya
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40006687$$D View this record in MEDLINE/PubMed
BookMark eNptks1vFCEYxiemxn7YuydD4sXLVBiGr5PZbLruJjUmrRpvhIV3VjYzsA4za-pfX7Zba7cRDvC-_Hjghee0OAoxQFG8IfiCUoU_bI21PkAiFFeY1PhFcVJhwUuq6I-jJ_Pj4jylNc5NESq5eFUc1zngXIqTYjvtY0rlNRg7-C2gmS0_g_NmAIcmYfDL6G7RNaRNDAkSGiJahKYdIfwxaD5BNwN0eXnlY0A-oPnYmYBuoDdoFts2_vZhlUOTYjAt-n5_YTNk-HXxsjFtgvOH8az4Nrv8Op2XV18-LaaTq9LWNRnK2jqu8r05Z4LVxLCqkYxXuFkSJxhVOWmlqh1zYJXDQjrGRSWopSAMh5qeFYu9rotmrTe970x_q6Px-j4R-5U2_eBtC7qRhFqCicRc1ZV1ikolWSMsW3IKGGetj3utzbjswFkIQ2_aA9HDleB_6lXcakIkx0LJrPD-QaGPv0ZIg-58stC2JkAck6ZE5B8irFYZffcMXcexz6-4pyrKpKD_qJXJFfjQxHyw3YnqiayUUoKI3SNc_IfK3UHnbTZV43P-YMPbp5U-lvjXNhnAe8Du3NND84gQrHfm1M_NSe8AyYfVeg
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
NPM
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines13020140
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed



Publicly Available Content Database
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_f813c101806942cd938985f7c5b63e00
PMC11860798
A829997174
40006687
10_3390_vaccines13020140
Genre Journal Article
GeographicLocations Japan
United States--US
GeographicLocations_xml – name: Japan
– name: United States--US
GrantInformation_xml – fundername: the Ministry of Health, Labour and Welfare, Japan
  grantid: 20HA2001
– fundername: The Japan Agency for Medical Research and Development
  grantid: JP23wm0125003
– fundername: Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B)
  grantid: 24K02498
– fundername: Intramural Research Program of the Center for Intractable Diseases and Immunogenomics (CiDIG), National Institutes of Biomedical Innovation, Health, and Nutrition
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP23wm0125003
– fundername: Ministry of Health, Labour, and Welfare, Japan
  grantid: 20HA2001
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
3V.
NPM
PMFND
7T7
7XB
8FD
8FK
C1K
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c441t-4cd690096657541a52f85620fb1d7539754c894d5dec9d078d567273c3e7a6e43
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:25:09 EDT 2025
Thu Aug 21 18:27:35 EDT 2025
Fri Jul 11 02:59:51 EDT 2025
Fri Jul 25 11:57:46 EDT 2025
Tue Jun 17 21:59:46 EDT 2025
Tue Jun 10 21:02:11 EDT 2025
Sat Mar 01 01:25:39 EST 2025
Tue Jul 01 01:11:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords influenza virus
vaccine
antibody-dependent cellular cytotoxicity
antibody-dependent cellular phagocytosis
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-4cd690096657541a52f85620fb1d7539754c894d5dec9d078d567273c3e7a6e43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3753-1211
0000-0003-1567-0667
0000-0002-6011-9631
0000-0003-2349-6320
0000-0003-3239-5249
0000-0002-6251-1696
0000-0003-3615-2631
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/vaccines13020140
PMID 40006687
PQID 3171235873
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_f813c101806942cd938985f7c5b63e00
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11860798
proquest_miscellaneous_3171381549
proquest_journals_3171235873
gale_infotracmisc_A829997174
gale_infotracacademiconefile_A829997174
pubmed_primary_40006687
crossref_primary_10_3390_vaccines13020140
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20250128
PublicationDateYYYYMMDD 2025-01-28
PublicationDate_xml – month: 1
  year: 2025
  text: 20250128
  day: 28
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Vaccines (Basel)
PublicationTitleAlternate Vaccines (Basel)
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
SSID ssj0000913867
Score 2.293083
Snippet Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their...
Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness...
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 140
SubjectTerms Antibodies
antibody-dependent cellular cytotoxicity
antibody-dependent cellular phagocytosis
Antigens
Avian flu
Cloning
Control
Cross-protection
Cytotoxicity
Domains
Dosage and administration
Enzymes
Epitopes
Evaluation
Health aspects
Hemagglutinins
Immune response
Immunization
Immunoglobulin G
Infections
Influenza
Influenza A
Influenza vaccines
influenza virus
Influenza viruses
Neutralization
Pandemics
Patient outcomes
Peptides
Phagocytosis
Proteins
vaccine
Vaccines
Viral antibodies
Viral infections
Viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQbwItMhIqQqrVJLYT-7hUrBakoqq0qDfLsR2xhyaITVstv54ZO91u4MCFwx42diTbM56ZL_Mi5G2hgi1cK5lUTXQzCoY1SJi0Vd2APpZlzOM-_lItzsXnC3mx1eoLY8JSeeB0cIetKriLZaYqLUrnNWhYJdvayabiIY9oHXTeFpiKMlgXXFV18ktywPWH19ahp3qFjjpEFRM9FMv1_y2Ut7TSNGJySwXNH5IHo-1IZ2nNj8i90D0m-yep-PT6gJ7d5VKtDug-PbkrS71-Qq6PcCHsNNgo4ujcsePYpyN4OuuGZdP7NT1NIbNhRYeefkoNTH5ZupjRr0O4hGEMX6bLjsaP_xQkjaVzYKX-BlQg_LXRsqff4jFEoj8l5_OPZ0cLNnZdYA5Mo4EJ5wExA7JBl4worCxbBUZS3jaFB2yj4aFTWnjpg9MeLAwv0ZvLHQ-1rYLgz8hO13fhBaGAlnSZcwdWioOXfNMITNh0IBN4gF9G3t_SwPxIxTUMgBKkl_mTXhn5gETazMOy2PEBMIsZmcX8i1ky8g5JbPDyAh2dHXMQYLlYBsvMFGhnDQhXZGR3MhMunZsO3zKJGS_9yoApFjOPa9jYm80wvomBbF3or9IcMJIAlWfkeeKpzZZENABVnRE14bbJnqcj3fJ7LAkOMLHKa61e_o9TekXul9jlOC9YqXbJzvDzKuyB6TU0r-Mt-w0aiCls
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH-C7sIFwfgKjMlIaAhp0fJhJ84JddOqgrSpKhvaLXJsZ_RAMpZsqPz1vOek7bJJHHJo7ERO37ef3-8BfAylVaEuhS9k4dKM3CcMEl-oJC3QHovI1XGfnCbTc_7tQlz0G25Nf6xypROdoja1pj3yA7Rzrqwzjb9c_fapaxRlV_sWGo9hC1WwlCPYOjw-nc3XuyyEeimTtMtPxhjfH9wqTRnrhhJ2FF0M7JGD7X-onO9Yp-HJyTumaPIMnvY-JBt3RH8Oj2y1DXuzDoR6uc_ONjVVzT7bY7MNPPXyBdwe0UL8uVVO1bGJ9k9cvw5r2LhqF0VtlmzeHZ21DWtr9rVrZPJXsemYfW_tLxymY8xsUTGXBGCocRSbIEvVf9AU4k_lPHz2w_0Njvgv4XxyfHY09fvuC75GF6n1uTYYOWOEQ6kZHioRlRKdpaAsQoMxToY3tcy4EcbqzKCnYQRldWMd21QllsevYFTVlX0DDKOmLApijd6KxodMUXAq3NSoG2KLlwefVzTIrzqQjRyDE6JXfp9eHhwSkdbzCB7b3aivL_Ne2vJShrF22GRJxiNtMnTLpChTLYoktgG-5BOROCchRjpq1dci4HIJDisfS7TSGUa63IOdwUwUPj0cXjFJ3gt_k29Y1YMP62F6kg60Vba-6eags4TRuQevO55afxJ3jqBMPZADbht883CkWvx00OAYLiZBmsm3_1_XO3gSUR9j2koKdmDUXt_Y9-hctcVuL0H_ABu3I5w
  priority: 102
  providerName: ProQuest
Title Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination
URI https://www.ncbi.nlm.nih.gov/pubmed/40006687
https://www.proquest.com/docview/3171235873
https://www.proquest.com/docview/3171381549
https://pubmed.ncbi.nlm.nih.gov/PMC11860798
https://doaj.org/article/f813c101806942cd938985f7c5b63e00
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZge-EF8ZvCqIyEhpBmSGI7sR8Q6qZVBalTVVbUtyixHagECbTZoPz13Dlpu8BeeOhDYyeKfWff9-V8d4S8CJXLQlNIJlXu3YyCYQ4SJrM4ycEey8jHcY_P4tFMfJjL-S48up3A1bXUDutJzZZfX__6sX4HC_4tMk6g7G8uM4NO6BX64JAw3CT7YJcSrGcwbsG-35d1yJUvKRsBeWdc83njt7z2IR075dP5_7tpX7Fa3ROVV0zU8A653WJLOmiU4S654cp75HDSJKdeH9HzXazV6oge0skubfX6Prk8wRdhU5f5LZAODRv7Oh7O0kFZL_LKrum0OVLrVrSu6PumwMnvjI4G9GPtvkEzHm-mi5J65wCFnSijQ1C16ieYSPibeeRPP_lp8ErxgMyGp-cnI9ZWZWAGoFPNhLHAqIH5oMtGhJmMCgUgKijy0AL30XDRKC2stM5oCwjESvT2csNdksVO8Idkr6xK95hQYFM6CrgBFGPgJpvnAgM6DewZ3MGvR15tZJB-b5JvpEBaUF7p3_LqkWMU0rYfps32F6rl57RdhWmhQm58zrJYi8hYDXBNySIxMo-5C-AhL1HEKaobyNFkbYwCvC6myUoHCqy3BgYseuSg0xMWpek2b5Qk3eh0ClDNRyYnMLDn22a8Ew-6la66aPoAiALW3iOPGp3aDkl4gKiSHlEdbeuMudtSLr74lOFAI-Mg0erJf8zoU3IrwmLHQcgidUD26uWFewYIrM77ZP_49Gwy7fsvGH2_zP4ADQ0vTw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLdGd4AL4pvAACPBENKiJbGdOAeEurGqZWtVlW7aLSS2Az2QjDXbVP4o_kbec9J2AYnbDjkkdiIn7_m938v7IuSNL03qq1y4QmbWzchdrEHiijSMMtDHIrB53MNR2D_mn0_F6Qb5vcyFwbDKpUy0glqXCv-R74Kes2mdEft49tPFrlHoXV220KjZ4tAsrsBkm38YfAL6vg2C3sF0v-82XQVcBaq_crnSYBECckeXA_dTEeQSQICXZ74G7B7DRSVjroU2KtagQbVAbyVTzERpaDiD594im5yFXtAhm3sHo_Fk9VcHq2zKMKr9oYzF3u5lqtBDPkcHIVozLf1n2wT8qwyuacN2pOY11de7R-42mJV2aya7TzZM8YBsj-ui14sdOl3ncM136DYdr8thLx6Sy31ciDsxqRWttKfcoe0PYjTtFtUsK_WCTupQXTOnVUkHdeOUXyntd-mXyvyAYQybprOCWqcDBQmX0h6wcHkFqhdOU2tR0BP7GSyzPSLHN0KXx6RTlIV5SihYaXHgMQXoSMFNOss4JooqkEXMwOGQ90saJGd1UY8EjCGkV_I3vRyyh0RazcNy3PZCef4taXZ3kkufKVsLLYx5oHQMMFCKPFIiC5nx4CHvkMQJCg2go0qb3AdYLpbfSroSUEEMljV3yFZrJmx21R5eMknSCJt5st4aDnm9GsY7MYCuMOVFPQfAmeCxQ57UPLV6JW6Bp4wcIlvc1nrn9kgx-25LkYN5GnpRLJ_9f12vyO3-dHiUHA1Gh8_JnQB7KHu-G8gt0qnOL8wLAHZV9rLZTZR8vekN_Af6M15N
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVEJcEG9cCiwSFCHVih9re31AKH1ECaVRFNqqN2PvrmkO2KVxW4Wfxq9jZu0kNUjcesghXttae17feF4Ab12hU1fmgR2IzIQZuU09SOwgDaMM7XHgmTruw1E4OOafT4PTNfi9qIWhtMqFTjSKWpWSvpF30c6Zss7I7-ZNWsR4r__p_KdNE6Qo0roYp1GzyIGeX6P7Nvs43ENav_O8_v7R7sBuJgzYEmFAZXOp0DtEFE_hB-6mgZcLBAROnrkKcXyMB6WIuQqUlrFCa6oCilz60tdRGmru433vwHpEXlEH1nf2R-PJ8gsPddwUYVTHRn0_drpXqaRo-YyCheTZtGyhGRnwr2G4YRnbWZs3zGD_Adxv8Cvr1Qz3ENZ08Qi2xnUD7Pk2O1rVc8222RYbr1pjzx_D1S5txJ7o1KhZ1pf2oZkVohXrFdU0K9WcTeq0XT1jVcmG9RCVXykb9NjXSv_AZUqhZtOCmQAEQ22Xsj6yc3mNZhj_psa7YCfmNRjGewLHt0KXp9ApykI_B4YeW-w5vkSkJPEilWWcikYl6iVf48-CDwsaJOd1g48EHSOiV_I3vSzYISItz6PW3OZAefE9aSQ9yYXrS9MXLYy5J1WMkFAEeSSDLPS1gzd5TyROSIEgHWXa1EHgdqkVV9ITiBBi9LK5BZutM1HwZXt5wSRJo3hmyUpMLHizXKYrKZmu0OVlfQ4CtYDHFjyreWr5SNyAUBFZIFrc1nrm9koxPTNtydFVDZ0oFhv_39druIuCm3wZjg5ewD2Pxik7ru2JTehUF5f6JWK8KnvVCBODb7ctv38AZF1igg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-Reactive+Fc-Mediated+Antibody+Responses+to+Influenza+HA+Stem+Region+in+Human+Sera+Following+Seasonal+Vaccination&rft.jtitle=Vaccines+%28Basel%29&rft.au=Nishiyama%2C+Ayae&rft.au=Nogimori%2C+Takuto&rft.au=Masuta%2C+Yuji&rft.au=Matsuura%2C+Tomoka&rft.date=2025-01-28&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=13&rft.issue=2&rft.spage=140&rft_id=info:doi/10.3390%2Fvaccines13020140&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines13020140
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon